

Pregnancy complications: The hidden PAD risk factor you're missing?

Written by The Life Science Feed Editorial Team · Published 8 October 2026 · Edited by Mara Voss

Peripheral artery disease (PAD) often presents as claudication or critical limb ischemia, but its origins can be far more subtle, extending back decades before symptoms manifest. While traditional risk factors like smoking, diabetes, and hyperlipidemia are well-established, emerging evidence points to a less commonly recognised precursor: complications during pregnancy. This connection suggests a need for a broader perspective on cardiovascular risk assessment in women.

The physiological demands of pregnancy can unmask underlying vascular vulnerabilities. Conditions such as pre-eclampsia, gestational hypertension, and gestational diabetes are not merely transient obstetric events; they are increasingly understood as early indicators of a woman's predisposition to future cardiovascular disease, including PAD. Understanding this link is essential for early intervention and risk mitigation, as a woman's long-term cardiovascular health is at stake.

KEY TAKEAWAYS

- **The Pivot:** Pregnancy complications are now recognised as independent risk factors for future peripheral artery disease.
- **The Data:** Specific obstetric histories, including pre-eclampsia and gestational diabetes, correlate with increased PAD incidence.
- **The Action:** Incorporate detailed obstetric history into cardiovascular risk stratification for women, particularly those presenting with atypical symptoms.

Peripheral artery disease, a condition characterised by narrowed arteries reducing blood flow to the limbs, affects millions globally. Its development is a complex relationship between genetic predisposition and environmental factors, with atherosclerosis as the primary underlying mechanism. The clinical presentation can range from asymptomatic to severe limb ischemia, often leading to significant morbidity and mortality if left unaddressed. Standard screening protocols typically focus on older patients with established risk factors, but this approach may overlook a substantial population of younger women with a history of pregnancy-related vascular stress.

The physiological adaptations required to sustain a pregnancy are profound, involving significant changes in cardiovascular, metabolic, and immune systems. When these adaptations fail or become dysregulated, complications such as pre-eclampsia, gestational hypertension, and gestational diabetes can arise. These conditions are not isolated events; they represent a stress test on the maternal vascular system, revealing inherent susceptibilities that can persist

long after delivery. The long-term implications of these obstetric complications extend beyond immediate maternal and fetal health, influencing a woman's cardiovascular trajectory for decades.

The vascular stress of pregnancy complications

Pre-eclampsia, characterised by new-onset hypertension and proteinuria after 20 weeks of gestation, is a particularly strong predictor of future cardiovascular disease. The pathophysiology involves widespread endothelial dysfunction, systemic inflammation, and impaired angiogenesis, all of which contribute to an atherogenic environment. These vascular changes do not simply resolve postpartum; they can leave a lasting imprint on the arterial tree, accelerating the atherosclerotic process. Women with a history of pre-eclampsia demonstrate persistent endothelial dysfunction, increased arterial stiffness, and altered lipid profiles years after their pregnancies. This sustained vascular damage sets the stage for conditions like PAD.

Gestational diabetes mellitus (GDM), another common pregnancy complication, also signals an increased risk for future vascular pathology. GDM is a state of glucose intolerance first recognised during pregnancy, often due to insulin resistance. Women who experience GDM have a significantly higher risk of developing type 2 diabetes later in life, a well-known and potent risk factor for PAD. But the connection extends beyond the development of overt diabetes. The metabolic dysregulation during GDM itself can induce microvascular and macrovascular changes, including oxidative stress and inflammation, which contribute directly to arterial damage. This means that even without progressing to type 2 diabetes, the GDM episode itself can prime the vasculature for future disease.

Other pregnancy complications, such as preterm birth and placental abruption, also correlate with an elevated risk of cardiovascular disease. While the mechanisms are less clearly defined than for pre-eclampsia or GDM, they often involve shared pathways of inflammation, oxidative stress, and vascular compromise. For instance, placental dysfunction, a common underlying factor in many adverse pregnancy outcomes, can lead to systemic maternal inflammation and endothelial injury. These systemic insults contribute to the overall burden of vascular damage, increasing the likelihood of developing conditions like PAD in the long term. Clinicians should consider the full spectrum of adverse pregnancy outcomes when assessing a woman's cardiovascular risk profile, as outlined in the ACOG maternal immunisation schedule.

The link between these obstetric complications and PAD is not merely an association; it reflects a shared underlying pathophysiology. The vascular and inflammatory pathways activated during complicated pregnancies mirror those involved in the development of atherosclerosis. This understanding shifts the perspective from viewing pregnancy complications as isolated events to recognising them as critical early markers in a woman's cardiovascular health continuum. Integrating this knowledge into routine clinical practice is essential for proactive risk management. For a comprehensive overview of obstetric care, the Oxford Handbook of Obstetrics and Gynaecology provides an excellent reference.

Implications for screening and prevention

Recognising pregnancy complications as risk factors for PAD necessitates a re-evaluation of current screening and prevention strategies. Traditional risk assessment tools, primarily developed in male populations, often underestimate cardiovascular risk in women. Incorporating a detailed obstetric history can significantly improve risk stratification, allowing for earlier identification of women at elevated risk for PAD and other cardiovascular diseases. This means asking

about pre-eclampsia, gestational diabetes, preterm birth, and recurrent pregnancy loss during routine health assessments, even years after the pregnancies have concluded.

For women with a history of these complications, intensified screening for traditional cardiovascular risk factors, such as hypertension, dyslipidemia, and diabetes, becomes paramount. Early detection and aggressive management of these modifiable risk factors can mitigate the long-term impact of pregnancy-related vascular stress. This might involve more frequent blood pressure monitoring, earlier lipid screening, and regular glucose tolerance tests. The goal is to interrupt the progression of subclinical atherosclerosis before it manifests as symptomatic PAD. This proactive approach contrasts with the reactive management often seen when PAD is diagnosed only after symptoms appear.

Lifestyle interventions play a critical role in prevention. Promoting healthy eating habits, regular physical activity, and smoking cessation in women with a history of pregnancy complications can substantially reduce their future cardiovascular risk. These interventions are not just about managing existing risk factors; they are about reversing or slowing the vascular damage initiated during pregnancy. Education about this long-term risk is also vital, empowering women to take an active role in their own health management. They need to understand that a complicated pregnancy is not just a past event, but a signal for future health considerations. This is particularly relevant given the challenges in managing conditions like obstetric antiphospholipid syndrome, where long-term management of the condition is essential for patient well-being.

But the challenge lies in translating this knowledge into actionable clinical practice. Many clinicians, particularly those outside of obstetrics, may not routinely inquire about detailed pregnancy histories. Integrating this information into electronic health records and developing clinical decision support tools could help bridge this gap. Long-term follow-up programs for women with complicated pregnancies could ensure ongoing surveillance and timely intervention. This requires a collaborative approach between obstetricians, general practitioners, and cardiologists, ensuring a continuum of care that extends well beyond the postpartum period. The long-term implications of myasthenia gravis in pregnancy also highlight the need for integrated care.

Addressing the knowledge gap in clinical practice

Despite the growing body of evidence, awareness of the link between pregnancy complications and future PAD remains suboptimal among many healthcare providers. This knowledge gap can lead to missed opportunities for early risk assessment and intervention. Clinicians may focus solely on immediate postpartum recovery, overlooking the critical window for long-term cardiovascular risk management. Education campaigns targeting primary care physicians, gynaecologists, and cardiologists are essential to disseminate this information and encourage a more holistic approach to women's health. The Oxford Handbook of Clinical Medicine offers a broad overview that can help bridge some of these inter-specialty gaps.

The lack of specific guidelines for PAD screening in women with a history of pregnancy complications is another significant barrier. While some guidelines acknowledge the increased cardiovascular risk associated with pre-eclampsia, explicit recommendations for PAD screening or intensified follow-up are often absent. Developing evidence-based guidelines that incorporate obstetric history into cardiovascular risk assessment algorithms would provide clear direction for clinicians. These guidelines should specify when and how to screen, what interventions are appropriate, and how to manage these patients over their lifespan. Without clear guidance, practice remains inconsistent.

Research is also needed to further elucidate the precise mechanisms linking specific pregnancy complications to PAD and

to identify optimal screening modalities. Longitudinal studies tracking women with complicated pregnancies into later life, coupled with advanced imaging techniques to detect subclinical atherosclerosis, could provide invaluable insights. Identifying specific biomarkers that predict future PAD risk in this population would also be a significant advance. This research would refine risk prediction models and allow for more targeted and efficient interventions, moving beyond broad associations to precise predictive tools. Understanding the nuances of conditions like maternal sepsis also requires ongoing research into predictive markers.

The economic burden of PAD is substantial, encompassing healthcare costs for diagnosis, treatment, and long-term management of complications like amputations. Proactive identification and prevention strategies, initiated based on pregnancy history, could lead to significant cost savings by reducing the incidence of symptomatic PAD and its associated morbidities. Investing in early risk assessment and intervention is not just a clinical imperative; it is also a public health priority. The long-term benefits of preventing PAD, both in terms of quality of life and healthcare expenditure, far outweigh the costs of early screening and lifestyle interventions. The next step is to integrate these insights into routine care, ensuring that a woman's pregnancy history is as central to her cardiovascular risk assessment as her cholesterol levels or blood pressure.

CLINICAL IMPLICATIONS

The connection between pregnancy complications and future peripheral artery disease is no longer a theoretical concept; it is a clinical reality that demands attention. Clinicians must move beyond the traditional, male-centric view of cardiovascular risk and actively solicit detailed obstetric histories from their female patients. A history of pre-eclampsia or gestational diabetes should immediately flag a woman for intensified surveillance and aggressive management of modifiable risk factors.

It is not enough to simply note these complications in a patient's chart. General practitioners, cardiologists, and gynaecologists need to collaborate to ensure a seamless transition of care and consistent messaging about long-term cardiovascular health. This means more than just a passing mention; it requires a structured approach to follow-up, potentially including earlier and more frequent screening for hypertension, dyslipidemia, and glucose intolerance.

The industry also has a role to play in developing better risk stratification tools that incorporate these unique female-specific risk factors. Current algorithms often fall short in accurately predicting cardiovascular events in women. Tailored tools, perhaps leveraging artificial intelligence to integrate complex obstetric and genetic data, could significantly improve early detection and guide more personalised preventive strategies. The goal is to prevent symptomatic PAD, not just treat it once it has already caused irreversible damage.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1.

1. Shamaki GR, Markson F, Soji-Ayoade D, Agwuegbo CC, Bamgbose MO, Tamunoinemi BM. Peripheral Artery Disease: A Comprehensive Updated Review. *Curr Probl Cardiol.* 2022;47(11):101082. doi:10.1016/j.cpcardiol.2021.101082
2. Nickles MA, Ennis WJ, O'Donnell TF Jr, Altman IA. Compression therapy in peripheral artery disease: a literature review. *J Wound Care.* 2023;32(Sup5):S25-S30. doi:10.12968/jowc.2023.32.Sup5.S25
3. Mandaglio-Collados D, Marín F, Rivera-Caravaca JM. Peripheral artery disease: Update on etiology, pathophysiology, diagnosis and treatment. *Med Clin (Barc).* 2023;161(8):344-350. doi:10.1016/j.medcli.2023.06.005
4. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. *Circ Res.* 2015;116(9):1509-26. doi:10.1161/CIRCRESAHA.116.303849
5. McDermott MM. Peripheral Artery Disease in the Legs. *N Engl J Med.* 2026;394(5):486-496. doi:10.1056/NEJMcp2501200
6. Aday AW, Matsushita K. Epidemiology of Peripheral Artery Disease and Polyvascular Disease. *Circ Res.* 2021;128(12):1818-1832. doi:10.1161/CIRCRESAHA.121.318535

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com